Skip to main content

Table 1 Baseline characteristics for conventionally treated (CTR group) and patients whose treatment was guided by BNP (BNP group) and for non-responders and responders (defined as a patient with a BNP < 300 ng/l and/or a decrease in BNP of at least 40 % in week 16 compared to BNP at study start) (ref art 2)

From: Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study

Characteristics BNP group CTR group p-value Responders Non-responders p-value
n = 147 n = 132 n = 78 n = 53
Background
 Age years (SD) 71.6 (±9.7) 70.1 (±10) 0.19 69.6 (±10.2) 74.0 (±8.1) 0.009
 Gender male, n (%) 107 (73 %) 96 (73 %) 0.99 63 (81 %) 34 (64 %) 0.33
 IHD n (%) 81 (55 %) 76 (58 %) 0.68 43 (55 %) 30 (57 %) 0.87
 Hypertension n (%) 39 (27 %) 30 (23 %) 0.46 35 (45 %) 25 (47 %) 0.80
 Diabetes Mellitus n (%) 39 (27 %) 48 (36 %) 0.08 19 (24 %) 13 (25 %) 0.98
Physical examination
 Heart rate beats/min (SD) 74 (±18) 73 (±19) 0.89 78 (±20) 71 (±15) 0.93
 Systolic blood pressure, mm Hg (SD) 126 (±22) 122 (±22) 0.12 126 (±23) 125 (±21) 0.77
 Diastolic blood pressure, mm Hg (SD) 75 (±13) 74 (±13) 0.42 75 (±13) 74 (±12) 0.71
NYHA functional classes
 II n (%) 47 (32 %) 36 (27 %) 0.39 28 18 0.09
 III n (%) 76 (52 %) 78 (59 %) 0.22 42 27 0.74
 IV n (%) 22 (15 %) 18 (14 %) 0.75 8 8 0.41
Medication
 ACEi n (%) 113 (77) 92 (70) 0.17 65 (83) 37 (70) 0.67
 ARB n (%) 51 (35) 46 (35) 0.98 23 (29) 23 (43) 0.10
 BB n (%) 137 (93) 125 (95) 0.60 75 (96) 48 (91) 0.19
 MRA n (%) 81 (55) 78 (59) 0.50 43 (55) 28 (55) 0.80
Echocardiography (LVEF)
 <30 % n 84 (57 %) 76 (58 %) 0.94 50 (64 %) 27 (51 %) 0.13
 30-40 % n 63 (43 %) 56 (42 %) 0.94 28 (36 %) 26 (49 %) 0.13
Laboratory results
 BNP ng/l mean (SD) 808 (±676) 899 (±915) 0.34 805 (±704) 778 (±651) 0.82
 eGFR mL/min/1.73 m2 mean (SD) 61.4 (±20.9) 60.1 (±20.9) 0.59 66.5 (±21.1) 56.1 (±19.2) 0.005
 Potassium mmol/l mean (SD) 4.3 (±0.5) 4.2 (±0.5) 0.38 4.3 (±0.50) 4.3 (±0.52) 0.80
  1. Notes: ACEi Angiotensin Converting Enzyme inhibitor, ARB Angiotensin receptor blockers, BB Beta blocker, BNP B-type natriuretic peptide, CTR Conventionally treated, eGFR estimated glomerular filtration rate (MDRD formula), IHD Ischemic Heart Disease, LVEF Left Ventricular Ejection Fraction, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association functional class, SD standard deviation